Boston Scientific Corp BSX
We take great care to ensure that the data presented and summarized in this overview for BOSTON SCIENTIFIC CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BSX
View all-
Vanguard Group Inc Valley Forge, PA138MShares$14.2 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY126MShares$13 Billion0.22% of portfolio
-
State Street Corp Boston, MA64.9MShares$6.67 Billion0.23% of portfolio
-
Bank Of America Corp Charlotte, NC33.9MShares$3.48 Billion0.23% of portfolio
-
Primecap Management CO Pasadena, CA33.1MShares$3.4 Billion2.56% of portfolio
-
Geode Capital Management, LLC Boston, MA32.7MShares$3.36 Billion0.21% of portfolio
-
Jpmorgan Chase & CO New York, NY28.3MShares$2.91 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA26.6MShares$2.74 Billion0.37% of portfolio
-
Morgan Stanley New York, NY20.7MShares$2.13 Billion0.13% of portfolio
-
Bollard Group LLC Boston, MA19.7MShares$2.03 Billion45.28% of portfolio
Latest Institutional Activity in BSX
Top Purchases
Top Sells
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at BSX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Arthur C Butcher EVP& Grp Pres, MedSurg & APAC |
SELL
Open market or private sale
|
Direct |
17,313
-42.32%
|
$1,748,613
$101.55 P/Share
|
|
Dec 01
2025
|
Arthur C Butcher EVP& Grp Pres, MedSurg & APAC |
BUY
Exercise of conversion of derivative security
|
Direct |
17,313
+10.68%
|
$380,886
$22.9 P/Share
|
|
Nov 28
2025
|
Miriam O'Sullivan SVP, Chief HR Officer |
SELL
Bona fide gift
|
Direct |
260
-1.73%
|
-
|
|
Nov 14
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Bona fide gift
|
Direct |
9,610
-5.41%
|
-
|
|
Nov 12
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Bona fide gift
|
Direct |
690
-0.39%
|
-
|
|
Nov 06
2025
|
Ellen M Zane Director |
SELL
Open market or private sale
|
Direct |
12,891
-34.82%
|
$1,263,318
$98.28 P/Share
|
|
Nov 03
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Open market or private sale
|
Direct |
50,000
-7.76%
|
$4,950,000
$99.88 P/Share
|
|
Nov 03
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.96%
|
$1,300,000
$26.15 P/Share
|
|
Oct 30
2025
|
Michael F Mahoney Chairman, President & CEO |
SELL
Bona fide gift
|
Indirect |
149,992
-41.24%
|
-
|
|
Oct 29
2025
|
Ellen M Zane Director |
BUY
Other acquisition or disposition
|
Direct |
12,891
+25.83%
|
-
|
|
Oct 29
2025
|
Michael F Mahoney Chairman, President & CEO |
BUY
Bona fide gift
|
Indirect |
162,193
+20.12%
|
-
|
|
Oct 28
2025
|
Ellen M Zane Director |
SELL
Open market or private sale
|
Direct |
2,901
-10.73%
|
$295,902
$102.24 P/Share
|
|
Oct 27
2025
|
Ellen M Zane Director |
SELL
Open market or private sale
|
Direct |
9,990
-26.98%
|
$1,008,990
$101.13 P/Share
|
|
Oct 01
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Open market or private sale
|
Direct |
50,000
-11.29%
|
$4,900,000
$98.65 P/Share
|
|
Oct 01
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.96%
|
$1,300,000
$26.15 P/Share
|
|
Sep 02
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
SELL
Open market or private sale
|
Direct |
50,000
-11.6%
|
$5,250,000
$105.37 P/Share
|
|
Sep 02
2025
|
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.96%
|
$1,300,000
$26.15 P/Share
|
|
Aug 02
2025
|
Jonathan Monson EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
528
-1.47%
|
$55,440
$105.41 P/Share
|
|
Aug 02
2025
|
Jonathan Monson EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,090
+2.95%
|
-
|
|
Aug 01
2025
|
Arthur C Butcher EVP& Grp Pres, MedSurg & APAC |
SELL
Open market or private sale
|
Direct |
17,313
-42.32%
|
$1,800,552
$104.63 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 282K shares |
|---|---|
| Other acquisition or disposition | 12.9K shares |
| Exercise of conversion of derivative security | 1.05M shares |
| Bona fide gift | 163K shares |
| Bona fide gift | 169K shares |
|---|---|
| Open market or private sale | 1.14M shares |
| Payment of exercise price or tax liability | 244K shares |